EPS for Soligenix, Inc. (SNGX) Expected At $-0.13; ISRA VISION AG ORDINARY SHARES GERMANY (IRAVF) Shorts Decreased By 2.44%

Soligenix, Inc. (NASDAQ:SNGX) Logo

Analysts expect Soligenix, Inc. (NASDAQ:SNGX) to report $-0.13 EPS on February, 8.After having $-0.11 EPS previously, Soligenix, Inc.’s analysts see 18.18% EPS growth. The stock decreased 0.01% or $0.0001 during the last trading session, reaching $0.8999. About 74,543 shares traded. Soligenix, Inc. (NASDAQ:SNGX) has declined 48.76% since February 1, 2018 and is downtrending. It has underperformed by 48.76% the S&P500.

ISRA VISION AG ORDINARY SHARES GERMANY (OTCMKTS:IRAVF) had a decrease of 2.44% in short interest. IRAVF’s SI was 8,000 shares in February as released by FINRA. Its down 2.44% from 8,200 shares previously. It closed at $64.05 lastly. It is down 0.00% since February 1, 2018 and is . It has by 0.00% the S&P500.

Another recent and important ISRA VISION AG (OTCMKTS:IRAVF) news was published by Seekingalpha.com which published an article titled: “Niche Machine Vision Player Near Major Inflection Point In Growth – Seeking Alpha” on February 13, 2017.

More notable recent Soligenix, Inc. (NASDAQ:SNGX) news were published by: Seekingalpha.com which released: “Soligenix nabs new patent in Europe – Seeking Alpha” on January 23, 2019, also Seekingalpha.com with their article: “Soligenix up 11% on European patent – Seeking Alpha” published on January 23, 2019, Nasdaq.com published: “Wall Street Seen Gaining on Upbeat Dow Component Earnings – Nasdaq” on January 23, 2019. More interesting news about Soligenix, Inc. (NASDAQ:SNGX) were released by: Nasdaq.com and their article: “US Futures Gain on Upbeat Dow Earnings – Nasdaq” published on January 23, 2019 as well as Seekingalpha.com‘s news article titled: “Soligenix to increase enrollment in late-stage study of SGX301 in CTCL – Seeking Alpha” with publication date: October 15, 2018.

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company has market cap of $15.91 million. It operates through two divisions, BioTherapeutics and Vaccines/BioDefense. It currently has negative earnings. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including pediatric Crohn's disease and acute radiation enteritis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.